Business
REG - Novacyt S.A. - Appointment of Joint Corporate Broker
REG - Novacyt S.A. - Appointment of Joint Corporate Broker
About this update from Novacyt Sas
RNS Number : 2058Z Novacyt S.A. 15 September 2025 Novacyt S.A.("Novacyt", the "Company" or the "Group")Appointment of Joint Corporate BrokerParis, France, and Manchester, UK - 15 September 2025 - Novacyt S.A. (EURONEXT GROWTH: ALNOV; AIM: NCYT), the international molecular diagnostics company with a broad portfolio of integrated technologies and services, announces the appointment of Singer Capital Markets as joint corporate broker to the Company, with immediate effect.Singer Capital Markets will work alongside SP Angel, the Company's Nominated Adviser and existing joint corporate broker.ContactsNovacyt SAhttps://novacyt.com/investorsLyn Rees, Chief Executive Officer Via Walbrook PRSteve Gibson, Chief Financial Officer SP Angel Corporate Finance LLP (Nominated Adviser and Broker)+44 (0)20 3470 0470Matthew Johnson / Charlie Bouverat (Corporate Finance)Vadim Alexandre / Rob Rees (Corporate Broking)Singer Capital Markets (Joint Broker)+44 (0) 20 7496 3000Tom Salvesen / Phil Davies / James Fischer / Samed EthemiAllegra Finance (French Listing Sponsor)Rémi Durgetto / Yannick Petit +33 (1) 42 22 10 10 [email protected] / [email protected] PR (Financial PR & IR)Paul McManus / Lianne ApplegarthAlice Woodings+44 (0)20 7933 8780 or [email protected]+44 (0)7980 541 893 / +44 (0)7584 391 303 +44 (0)7407 804 654About Novacyt Group (www.novacyt.com)Novacyt is an international molecular diagnostics company providing a broad portfolio of integrated technologies and services, primarily focused on the delivery of genomic medicine. The Company develops, manufactures, and commercialises a range of molecular assays and instrumentation to deliver workflows and services that enable seamless end-to-end solutions from sample to result across multiple sectors including human health, animal health and environmental.The Company is divided into three business segments:ClinicalBroad portfolio of human clinical in vitro diagnostic products, workflows and services focused on three therapeutic areas:· Reproductive Health: NIPT, Cystic Fibrosis and other rapid aneuploidy tests· Precision Medicine: DPYD genotyping assay· Infectious Diseases: Winterplex, multiplex winter respiratory PCR panelInstrumentationPortfolio of next generation size selection DNA sample preparation platforms and rapid PCR machines, including:· Ranger® Technology: automated DNA sample...